Alpha 2.0
Login Register
» Authors » Leona Plum-Morschel

Leona Plum-Morschel

Explore the profile of Leona Plum-Morschel including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 32
Citations 360
Followers 0
Related Specialties
Endocrinology
Pharmacology
Gastroenterology
Top 10 Co-Authors
Tim Heise
Eric Zijlstra
Grit Andersen
Ulrike Hovelmann
Thomas Forst
Christoph Kapitza
Jennifer Leohr
Anne Flint
Mary Anne Dellva
Theresa Herbrand
Published In
Diabetes Obes Metab
Aliment Pharmacol Ther
J Diabetes Sci Technol
Clin Pharmacokinet
Clin Drug Investig
Affiliations
Soon will be listed here.
Recent Articles
1.
Pharmacokinetic Properties of a Once-Weekly Fixed-Ratio Combination of Insulin Icodec and Semaglutide Compared with Separate Administration of Each Component in Individuals with Type 2 Diabetes Mellitus
Westergaard L, Alifrangis L, Buckley S, Coester H, Klitgaard T, Kristensen N, et al.
Clin Drug Investig . 2024 Nov; 44(11):849-861. PMID: 39488821
Background And Objective: IcoSema is being developed as a subcutaneous once-weekly fixed-ratio combination of the once-weekly basal insulin icodec and the once-weekly glucagon-like peptide-1 receptor agonist semaglutide. This study investigated...
2.
Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusion
Leohr J, Dellva M, LaBell E, Coutant D, Arrubla J, Plum-Morschel L, et al.
Diabetes Obes Metab . 2023 Oct; 26(1):215-223. PMID: 37814517
Aims: To compare the time to hyperglycaemia recovery after ultra rapid lispro (URLi; Lyumjev®) versus Humalog in a randomized, double-blind crossover study. Materials And Methods: Thirty-two adults with type 1...
3.
Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU- und US-sourced reference insulins
Chen W, Lu J, Plum-Morschel L, Andersen G, Zijlstra E, He A, et al.
Diabetes Obes Metab . 2023 Sep; 25(12):3817-3825. PMID: 37735841
Aim: For the successful approval and clinical prescription of insulin biosimilars, it is essential to show pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence to the respective reference products sourced from the...
4.
Noninvasive Continuous Glucose Monitoring With a Novel Wearable Dial Resonating Sensor: A Clinical Proof-of-Concept Study
Handy C, Chaudhry M, Qureshi M, Love B, Shillingford J, Plum-Morschel L, et al.
J Diabetes Sci Technol . 2023 Apr; 18(6):1408-1415. PMID: 37102600
Background: A noninvasive, wearable continuous glucose monitor would be a major advancement in diabetes therapy. This trial investigated a novel noninvasive glucose monitor which analyzes spectral variations in radio frequency/microwave...
5.
Oral insulin: A history of ambition, failure and data torturing
Heise T, Plum-Morschel L, Zijlstra E
Diabetes Obes Metab . 2023 Jan; 25(4):940-942. PMID: 36692379
No abstract available.
6.
Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes
Heller S, Battelino T, Bailey T, Pieber T, Hovelmann U, Plum-Morschel L, et al.
Diabetes Obes Metab . 2023 Jan; 25(5):1351-1360. PMID: 36692230
Aims: To perform an integrated analysis of the safety and efficacy of dasiglucagon, a glucagon analogue available in a ready-to-use aqueous formulation, to treat severe hypoglycaemia (SH) in type 1...
7.
Pharmacokinetic and Pharmacodynamic Characteristics of Insulin Icodec After Subcutaneous Administration in the Thigh, Abdomen or Upper Arm in Individuals with Type 2 Diabetes Mellitus
Plum-Morschel L, Andersen L, Hansen S, Hovelmann U, Krawietz P, Kristensen N, et al.
Clin Drug Investig . 2023 Jan; 43(2):119-127. PMID: 36631720
Background And Objective: Individuals with diabetes mellitus may prefer different body regions for subcutaneous insulin administration. This trial investigated whether choice of injection region affects exposure and glucose-lowering effect of...
8.
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906
Jungnik A, Arrubla Martinez J, Plum-Morschel L, Kapitza C, Lamers D, Thamer C, et al.
Diabetes Obes Metab . 2022 Dec; 25(4):1011-1023. PMID: 36527386
Aim: To report two phase I studies of the novel subcutaneous glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) dual agonist BI 456906 versus placebo in healthy volunteers and people with overweight/obesity. Materials...
9.
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity
Bianzano S, Nordaby M, Plum-Morschel L, Peil B, Heise T
Diabetes Obes Metab . 2022 Dec; 25(3):832-843. PMID: 36478142
Aims: To study the oral 11 beta-hydroxysteroid dehydrogenase-1 (11β-HSD1) inhibitor BI 187004 (NCT02150824), as monotherapy and in combination with metformin, versus placebo in patients with type 2 diabetes mellitus (T2DM)...
10.
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US-licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE-3 (Recombinant Human INsulin Equivalence-3) study
Plum-Morschel L, Klein O, Singh G, Murugesan S, Marwah A, Sharma N, et al.
Diabetes Obes Metab . 2022 May; 24(9):1819-1828. PMID: 35589611
Aim: To establish the pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of proposed biosimilar insulin 70/30 (Biocon's Insulin-70/30) and HUMULIN® 70/30 (HUMULIN-70/30; Eli Lilly and Company, IN). Materials And Methods: In...